Stay updated on Ipilimumab+Nivolumab for Stage IV IBC Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab+Nivolumab for Stage IV IBC Clinical Trial page.

Latest updates to the Ipilimumab+Nivolumab for Stage IV IBC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe record describes a terminated Phase 2 study of ipilimumab and nivolumab for recurrent HER2-negative inflammatory breast cancer, including its eligibility criteria, study outcomes, and a linked protocol document.SummaryDifference63%

- Check18 days agoChange DetectedThe site footer now identifies the release as v3.8.0 instead of v3.7.2, while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide NIH notice announces a transition to using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI), with a link to transition updates and FAQs.SummaryDifference1%

- Check32 days agoChange DetectedThe footer now displays site revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer’s site revision number changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check60 days agoChange DetectedThe study page now shows a 403 Forbidden error instead of the usual study details, indicating an access restriction or server issue.SummaryDifference21%

Stay in the know with updates to Ipilimumab+Nivolumab for Stage IV IBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab+Nivolumab for Stage IV IBC Clinical Trial page.